Variant Gene Risk Allele Score vda Association Type Original DB Sentence supporting the association PMID PMID Year
dbSNP: rs113488022
rs113488022
0.090 GeneticVariation BEFREE Both the HP and TSA exhibited the V600E BRAF mutation without MSI or MMR deficiency. 17914558

2007

dbSNP: rs121913377
rs121913377
0.090 GeneticVariation BEFREE Both the HP and TSA exhibited the V600E BRAF mutation without MSI or MMR deficiency. 17914558

2007

dbSNP: rs113488022
rs113488022
0.090 GeneticVariation BEFREE BRAF V600E mutation analysis was performed in 148 selected cases; mutations were found in 44/49 (90%) of lesions diagnosed as sessile serrated adenoma, in 10/34 (29%) of hyperplastic polyps of microvesicular type, in 4/11 (36%) of traditional serrated adenomas, in 10/10 (100%) of mixed hyperplastic adenomatous polyps, and in 2/42 (5%) of "conventional" adenomas. 19126563

2009

dbSNP: rs121913377
rs121913377
0.090 GeneticVariation BEFREE BRAF V600E mutation analysis was performed in 148 selected cases; mutations were found in 44/49 (90%) of lesions diagnosed as sessile serrated adenoma, in 10/34 (29%) of hyperplastic polyps of microvesicular type, in 4/11 (36%) of traditional serrated adenomas, in 10/10 (100%) of mixed hyperplastic adenomatous polyps, and in 2/42 (5%) of "conventional" adenomas. 19126563

2009

dbSNP: rs113488022
rs113488022
0.090 GeneticVariation BEFREE BRAF V600E mutations were seen in 83% of proximal and 74% of distal hyperplastic polyps. 19855373

2010

dbSNP: rs121913377
rs121913377
0.090 GeneticVariation BEFREE BRAF V600E mutations were seen in 83% of proximal and 74% of distal hyperplastic polyps. 19855373

2010

dbSNP: rs113488022
rs113488022
0.090 GeneticVariation BEFREE BRAF mutations (V600E) were observed in 45.8% (11 of 24) of HPs, 60.9% (14 of 23) of SSAs, and 63.6% (7 of 11) of SSANs, and were equally found in both SSA and carcinoma/HGD areas of the individual SSANs. 21263251

2011

dbSNP: rs121913377
rs121913377
0.090 GeneticVariation BEFREE BRAF mutations (V600E) were observed in 45.8% (11 of 24) of HPs, 60.9% (14 of 23) of SSAs, and 63.6% (7 of 11) of SSANs, and were equally found in both SSA and carcinoma/HGD areas of the individual SSANs. 21263251

2011

dbSNP: rs1801166
rs1801166
APC
0.010 GeneticVariation BEFREE Four patients had a germ-line E1317Q missense variant of APC that was not present in controls; one of these individuals had an unusually large number of metaplastic polyps of the colorectum. 9724771

1998

dbSNP: rs17655
rs17655
0.010 GeneticVariation BEFREE In a Minnesota-based case-control study of cases with only adenomatous polyps (n = 384), only hyperplastic polyps (n = 191), or both types of polyps (n = 119) versus polyp-free controls (n = 601), we investigated the role of polymorphisms in the DNA repair genes O(6)-methylguanine methyltransferase (MGMT; p.L84F and p.I143V), XPD (p.D312N and p.K751Q), and XPG (p.D1104H). 16284370

2005

dbSNP: rs1799977
rs1799977
0.010 GeneticVariation BEFREE In a Minnesota-based case-control study of individuals with adenomas (N=401), hyperplastic polyps (N=195), or both adenomas and hyperplastic polyps (N=123) versus polyp-free controls (N=624), we investigated the role of hMLH1-93G>A, hMLH1 I219V, and hMSH6 G39E polymorphisms in increasing the risk of colorectal polyps. 16771955

2006

dbSNP: rs536562413
rs536562413
0.010 GeneticVariation BEFREE In a Minnesota-based case-control study of individuals with adenomas (N=401), hyperplastic polyps (N=195), or both adenomas and hyperplastic polyps (N=123) versus polyp-free controls (N=624), we investigated the role of hMLH1-93G>A, hMLH1 I219V, and hMSH6 G39E polymorphisms in increasing the risk of colorectal polyps. 16771955

2006

dbSNP: rs1042821
rs1042821
0.010 GeneticVariation BEFREE In a Minnesota-based case-control study of individuals with adenomas (N=401), hyperplastic polyps (N=195), or both adenomas and hyperplastic polyps (N=123) versus polyp-free controls (N=624), we investigated the role of hMLH1-93G>A, hMLH1 I219V, and hMSH6 G39E polymorphisms in increasing the risk of colorectal polyps. 16771955

2006

dbSNP: rs113488022
rs113488022
0.090 GeneticVariation BEFREE In a multivariate analysis, presence of villous histology and high-grade dysplasia was associated with KRAS mutations (OR, 3.0; 95% CI, 1.7-5.4 and OR, 3.5; 95% CI 1.9-6.5, respectively), while serrated adenomas and hyperplastic polyps were associated with BRAF V600E mutations (OR, 20.6; 95% CI, 8.2-51.8 and OR, 11.9; 95% CI 4.9-29.0, respectively). 26910894

2016

dbSNP: rs121913377
rs121913377
0.090 GeneticVariation BEFREE In a multivariate analysis, presence of villous histology and high-grade dysplasia was associated with KRAS mutations (OR, 3.0; 95% CI, 1.7-5.4 and OR, 3.5; 95% CI 1.9-6.5, respectively), while serrated adenomas and hyperplastic polyps were associated with BRAF V600E mutations (OR, 20.6; 95% CI, 8.2-51.8 and OR, 11.9; 95% CI 4.9-29.0, respectively). 26910894

2016

dbSNP: rs6733868
rs6733868
0.010 GeneticVariation BEFREE In addition, the number of minor alleles of both rs6733868 and rs13428812 was significantly correlated with the risk of <i>Helicobacter pylori</i> (HP) infection (P=0.0070 and P=0.0050, respectively). 30867787

2019

dbSNP: rs13428812
rs13428812
0.010 GeneticVariation BEFREE In addition, the number of minor alleles of both rs6733868 and rs13428812 was significantly correlated with the risk of <i>Helicobacter pylori</i> (HP) infection (P=0.0070 and P=0.0050, respectively). 30867787

2019

dbSNP: rs1042522
rs1042522
0.010 GeneticVariation BEFREE In conclusions, p53 Arg72Pro polymorphism is a potential marker of HP infection-related HNSCC rather than a susceptibility gene polymorphism. 24289637

2013

dbSNP: rs1131691014
rs1131691014
0.010 GeneticVariation BEFREE In conclusions, p53 Arg72Pro polymorphism is a potential marker of HP infection-related HNSCC rather than a susceptibility gene polymorphism. 24289637

2013

dbSNP: rs878854066
rs878854066
0.010 GeneticVariation BEFREE In conclusions, p53 Arg72Pro polymorphism is a potential marker of HP infection-related HNSCC rather than a susceptibility gene polymorphism. 24289637

2013

dbSNP: rs1057519847
rs1057519847
0.010 GeneticVariation BEFREE Intense expression of L858R in the MP component was suggested, and the MP+ patients harboring L858R were at comparatively higher risk of recurrence in the group with pN0M0 lung adenocarcinoma. 31732945

2020

dbSNP: rs1057519848
rs1057519848
0.010 GeneticVariation BEFREE Intense expression of L858R in the MP component was suggested, and the MP+ patients harboring L858R were at comparatively higher risk of recurrence in the group with pN0M0 lung adenocarcinoma. 31732945

2020

dbSNP: rs121434568
rs121434568
0.010 GeneticVariation BEFREE Intense expression of L858R in the MP component was suggested, and the MP+ patients harboring L858R were at comparatively higher risk of recurrence in the group with pN0M0 lung adenocarcinoma. 31732945

2020

dbSNP: rs113488022
rs113488022
0.090 GeneticVariation BEFREE Our results also provide evidence that--just as BRAF V600E mutations in hyperplastic polyps and benign nevi- a mutated driver gene does not imply malignant behavior per se but may set the basis for malignant transformation. 26493284

2016

dbSNP: rs121913377
rs121913377
0.090 GeneticVariation BEFREE Our results also provide evidence that--just as BRAF V600E mutations in hyperplastic polyps and benign nevi- a mutated driver gene does not imply malignant behavior per se but may set the basis for malignant transformation. 26493284

2016